Core Scientific, Inc. CORZ
What this company does
Written from the business description in Core Scientific, Inc./tx's annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at +39.5% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.3 | 0.5 | 0.5 | 0.6 | 0.5 | 0.1 |
| Operating income $B | −0.2 | −0.1 | 0.0 | −2.1 | 0.1 | −0.0 |
| EBITDA $B | −0.2 | −0.0 | 0.1 | −1.9 | 0.2 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 |
| Net income $B | −0.3 | −1.4 | −0.2 | −2.1 | 0.0 | −0.0 |
| Free cash flow $B | −0.5 | −0.1 | 0.0 | −0.2 | −0.1 | −0.0 |
| EPS, diluted $ | −0.88 | −4.87 | −0.65 | −6.30 | 0.20 | −0.14 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | · | · | · | −460.7 | 6.6 | −13.7 |
| Shares out B | 0.31 | 0.29 | 0.39 | 0.38 | 0.27 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.